Navigation Links
Common Diabetes Drug May Fight Cancer
Date:9/14/2009

Metformin-chemo combination shrinks tumors, delays recurrence in mice: study

MONDAY, Sept. 14 (HealthDay News) -- Adding the widely used diabetes drug metformin to conventional chemotherapy shows promise for treating and delaying recurrence of breast cancer, new research suggests.

In lab tests using mice with breast cancer, researchers found that the drug combination suppressed the cancer stem cells thought to drive tumor progression.

"We discovered that metformin selectively kills cancer stem cells. Very few compounds do that," said Kevin Struhl, lead researcher of a paper appearing in the Sept. 14 online early edition of Cancer Research.

Stem cells are resistant to chemotherapy, and scientists had hoped to find a compound that kills them. "The basic idea in the stem cell hypothesis is that standard chemotherapy can kill the cancer cells that make up the bulk of the tumor, but it's not getting the stem cells, so they re-grow and the tumor comes back. That's a classic pattern," said Struhl, a professor of biological chemistry and molecular pharmacology at Harvard Medical School.

That metformin is a known compound adds to the good news. "The exciting thing was that they found an old and relatively safe compound and showed that it had a property that was selectively toxic to cancer stem cells," said Dr. Jonathan Chernoff, deputy scientific director at Fox Chase Cancer Center in Philadelphia. "That's new."

Metformin, which is marketed under the brand names Glucophage, Riomet, Fortamet, Glumetza, Obimet, Dianben and Diabex, is an agent that makes the body more sensitive to insulin. Over decades, millions of people have taken it.

"It's known that diabetics who take metformin have a much lower cancer incidence than diabetics who don't, so there has been a hint that the drug might be useful," said Struhl.

One recent study found that metformin may lower a diabetic patient
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. UK junior doctors gaining less experience of common procedures
2. New insights into common knee injuries
3. High and mighty: first common height gene identified by researchers behind obesity gene finding
4. Figure Skater Peggy Fleming, HealthSaver Says: Take Pains For Back Strains, 2nd Most Common Doctor Complaint
5. Exelixis Commences Public Offering of Common Stock
6. Common misdiagnosis: most women believe they have a yeast infection when they dont
7. Business Executives Discuss National Health Care Reform at Conference Sponsored by The Century Foundation, with Support from The Commonwealth Fund, and AARP
8. New Expert Report Dispels Common Myths About Aspartame
9. Common Foot Myths Trip Us Up
10. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
11. Allergy-Induced Asthma More Common in Affluent Countries
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Diabetes Drug May Fight Cancer
(Date:5/28/2015)... May 28, 2015 CompanionDx ... company, announces that it will present their integrated ... testing at the annual American Society of Clinical ... sequencing evaluates the DNA in a patient’s tumor ... analyzed for key changes or somatic mutations. Pharmacogenomics ...
(Date:5/28/2015)... Beverly Hills, CA (PRWEB) May 28, 2015 ... a novel interactive keratoconus web application to ... Keratoconus has expanded in the last few years. This ... Even eye doctors are not aware of the nuances ... the Khanna Vision Institute, realized that websites can be ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Sexual ... technology that advances sexual health and wellbeing in ... University of San Francisco (USF) will be the ... sexual assault recording and reporting system. , ... transparent, and confidential reporting experience for college sexual ...
(Date:5/28/2015)... DC (PRWEB) May 28, 2015 ... designing and implementing innovative models of care for ... to support alternative reimbursements and help operationalize contracting ... Optimity also unveils a bi-weekly series of seven ... developing Outcomes Based Contracting. Optimity is a strategy, ...
(Date:5/28/2015)... May 28, 2015 Cancer survivors who ... improvements in physical activity, fitness and quality of life, ... Yale Cancer Center and Jennifer Ligibel, MD, senior physician ... Dana Farber Cancer Institute. The findings will be presented ... (ASCO) Annual Meeting in Chicago. , ...
Breaking Medicine News(10 mins):Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Dr.Khanna Announced the Release of an Interactive Web Application for Keratoconus Treatment 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 2Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 3Health News:LIVESTRONG at the YMCA Program Shows Significant Gains for Cancer Survivor Participants 4
... , , , HARRISBURG, ... individuals have received free dental care, valued at nearly $160,000, ... dental insurer United Concordia Dental. , , ... commitment to provide free preventive services to those who cannot ...
... , MIAMI, July 23 Following a ... and a leader in sports nutrition for over 40 years, continues ... weekend Twinlab,s 2009 Mobile Beach Bash ... Miami, Florida. For those eager to show-off their six-pack abs for ...
... , SUNRISE, Fla., July 23 ... delivering intelligent devices and biologics that help monitor, diagnose and ... MARVEL-1 data for presentation at the Heart Failure Society of ... , Chris O,Connor, MD, Head ...
... has shown that risky driving habits are putting young ... of their perceptions about road safety. The study surveyed ... police. Young drivers involved in the study who said ... crash. Previous research has confirmed risky, ...
... Beauty Professionals Encouraged to Share Educational Materials ... , , WASHINGTON, July 23 ... service program created to help women cope with the appearance-related changes of ... Cosmetology Association (NCA) to generate awareness and increase program participation during its ...
... , , , SAN ... OREX ) today announced that it has priced an underwritten ... a price of $7.50 per share. Net proceeds, after estimated ... $70.9 million. Orexigen has granted the underwriter a 30-day option ...
Cached Medicine News:Health News:More than 1,000 Underinsured and Uninsured Individuals Receive Free Dental Care 2Health News:Twinlab's(R) Mobile Beach Bash Heats Up After a Successful Kick-Off of the 2009 RateYourAbs.com Contest 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 2Health News:Bioheart Announces Acceptance of Marvel-1 Data for Presentation at the Heart Failure Society of America (HFSA) Meeting 3Health News:Risky driving puts P-platers at high danger of crash 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 2Health News:Look Good...Feel Better Launches Salon Awareness Campaign During National Breast Cancer Awareness Month 3Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2
(Date:5/28/2015)...  The recent flurry of PBM mergers and ... scrambling to identify a pharmacy benefit manager that ... retail pharmacy chain, or other potentially conflicting entity. ... Catamaran, Rite Aid,s $2 billion acquisition of EnvisionRx, ... $10 billion are just the latest examples of ...
(Date:5/28/2015)... May 28, 2015   Sanovas, Inc., a rapidly ... the Top 50 Start-Up Companies in the World at the Silicon ... Logo - http://photos.prnewswire.com/prnh/20150528/219097LOGO ... segment experts with direct domain experience screened 2,716 companies from ... Property, Business Model, and Team. This select list was further ...
(Date:5/28/2015)... 28, 2015  Array BioPharma Inc. (NASDAQ: ARRY ... (licensed to AstraZeneca) at the 2015 American Society of ... May 29 – June 2, 2015 in ... advancing in a total of 6 pivotal trials, with ... (binimetinib monotherapy in NRAS mutant melanoma patients) and SUMIT ...
Breaking Medicine Technology:Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3Sanovas Awarded Global "Top-50" Start-Up Company 2Sanovas Awarded Global "Top-50" Start-Up Company 3Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 2Array BioPharma Announces Clinical Data Presentations At The 2015 ASCO Annual Meeting 3
... /PRNewswire/ -- Asenapine -- an,investigational drug being developed ... Nobel, for bipolar I disorder and,schizophrenia -- was ... acute manic and mixed episodes associated with bipolar,I ... a study,presented at the American Psychiatric Association's 2007 ...
... Presented at 2007 APA Meeting -, COLLEGEVILLE, ... four new studies examining safety and efficacy ... studied as a potential treatment for adults,with ... at the,2007 American Psychiatric Association annual meeting ...
Cached Medicine Technology:Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8
1.25 mm x 2.5 mm blade. 135 degrees back scratcher. Round handle....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. Designated most popular model or size....
4 mm wide tip....
Medicine Products: